{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', '5.4.', 'Scientific Rationale for Study Design', 'This study has a 28-week Treatment Period ending with a 4-week evaluation period from', 'Week 24 to Week 28. At the Day 1 visit the subjects will be randomized to the', 'daprodustat or placebo arm by the IRT system and the study treatment will be', 'administered in a blinded manner. From Day 1 to Week 24 participant study treatment', 'dosage will be adjusted, per the dosing algorithm (Section 7.2), in a blinded fashion, by', 'the IRT system.', 'A placebo control will enable assessment of the magnitude of the daprodustat response', 'and comparisons for safety data. Additionally, a placebo comparator allows for an', 'assessment of the extent to which any improvement in symptoms and HRQoL observed', \"in the daprodustat treatment group is due to the drug's effect.\", 'The risk of drop-outs due to lack of treatment effect is estimated to also be low in this', 'patient population since, prior clinical studies have indicated that non-dialysis, CKD', 'patients can maintain, or even increase, their current level of Hgb value without requiring', 'frequent interventional therapy with rhEPOs or IV iron for anemia [Skali, 2013].', 'Participants eligible for this study will be na\u00efve to rhEPO therapies and have limited IV', 'iron exposure at the time of screening and randomization, but may be receiving oral iron', 'which will be allowed to continue during the course of the study. Participants may start', 'treatment or change their dose of iron (oral, or IV if intolerable to oral) to maintain their', 'iron levels during the study. Participants who experience worsening of their anemia', 'during the study may receive rescue therapy based upon the protocol defined rescue', 'algorithm. Therefore, the use of a placebo arm in this study does not represent the', 'absence of any treatment for anemia, but rather placebo in addition to appropriate', 'standard of care.', '5.5.', 'Dose Justification', 'Daprodustat starting doses were selected to enable the majority of study participants to', 'reach the target Hgb concentration after approximately one red blood cell (RBC) lifespan', 'of treatment (almost 3 months, pharmacodynamic steady-state), without the need for any', 'individual dose adjustments. However, due to the between-participant variability in Hgb', 'response to a given dose of daprodustat and the relatively narrow Hgb target range,', 'individual dose adjustments of daprodustat are still expected during the first few months', 'of treatment.', 'The daprodustat starting doses and dose steps (including the highest dose level, 16 mg)', 'were based on dose exposure-response longitudinal modeling of Hgb data collected', 'across the Phase 2 program.', 'In this study, the starting dose of daprodustat will be 2 or 4 mg based on baseline', 'Hemocue Hgb, or a matching placebo dose, for all participants. The starting dose is', 'estimated to increase steady-state Hgb on average by approximately 1g/dL. This starting', 'dose is consistent with the dosing algorithm being evaluated in the Phase 3 study', '[GlaxoSmithKline Document Number 2015N230102_03] for non-dialysis dependent', 'participants who are not currently receiving rhEPO therapy.', '38']['2016N298481_02', 'CONFIDENTIAL', '205270', '6.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants will be eligible for inclusion in this study only if all of the following criteria', 'apply at screening (Week -4 and Week -2) and randomization (Day 1), unless', 'otherwise specified:', 'Age', '1. > 18 years of age at the time of signing the informed consent.', 'Type of Participant and Disease Characteristics', '2. CKD: Have CKD, confirmed at screening: Kidney Disease Outcomes Quality', 'Initiative (KDOQI) CKD stages 3, 4, or 5 defined by Estimated glomerular', 'filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI)', 'formula [Levey, 2009].', '3. Hgb: Stable HemoCue Hgb from 8.5 to 10.5 at screening visit (Week -4) and', 'from 8.5 to 10.0 g/dL at randomization (Day 1) (Section 9.1).', '4. IV Iron: Participants may receive up to one IV iron dose within the 8 weeks prior', 'to screening and NO IV iron use between screening visit and randomization (Day', '1).', '5. Oral Iron: If needed, participant may be on stable maintenance oral iron', 'supplementation. There should be <50% change in overall dose and no change in', 'type of iron prescribed doses in the 4 weeks prior to Day 1 randomization visit.', 'Sex', '6. Male and female participants are eligible. A female participant is eligible to', 'participate if she is not pregnant (see Section 12.4), not breastfeeding, and at least', 'one of the following conditions applies:', 'Not a woman of childbearing potential (WOCBP) as defined in Section', '12.4 (Appendix 4), or', 'A WOCBP who agrees to follow the contraceptive guidance in', 'Appendix 4 during the treatment period and for at least 4 weeks after the', 'last dose of study treatment.', 'Informed Consent', '7.', 'Capable of giving signed informed consent as described in Section 12.2', 'Appendix 2 which includes compliance with the requirements and restrictions', 'listed in the informed consent form (ICF) and in this protocol.', '39']\n\n###\n\n", "completion": "END"}